12 research outputs found
IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery
The rapidly growing interest in the application of nanoscience in the future design of radiopharmaceuticals and the development of nanosized radiopharmaceuticals in the late 2000 ' s, resulted in the creation of a Coordinated Research Project (CRP) by the International Atomic Energy Agency (IAEA) in 2014. This CRP entitled 'Nanosized delivery systems for radiopharmaceuticals' involved a team of expert scientist from various member states. This team of scientists worked on a number of cutting-edge areas of nanoscience with a focus on developing well-defined, highly effective and site-specific delivery systems of radiopharmaceuticals. Specifically, focus areas of various teams of scientists comprised of the development of nanoparticles (NPs) based on metals, polymers, and gels, and their conjugation/encapsulation or decoration with various tumor avid ligands such as peptides, folates, and small molecule phytochemicals. The research and development efforts also comprised of developing optimum radiolabeling methods of various nano vectors using diagnostic and therapeutic radionuclides including Tc-99m, Ga-68, Lu-177 and Au-198. Concerted efforts of teams of scientists within this CRP has resulted in the development of various protocols and guidelines on delivery systems of nanoradiopharmaceuticals, training of numerous graduate students/post-doctoral fellows and publications in peer reviewed journals while establishing numerous productive scientific networks in various participating member states. Some of the innovative nanoconstructs were chosen for further preclinical applications-all aimed at ultimate clinical translation for treating human cancer patients. This review article summarizes outcomes of this major international scientific endeavor
Education and training for the Radiation Safety Related to the Radiopharmaceutical
Objectives: The importance of education and training for
the radiation safety related to the radiopharmaceuticals
became a need in all area of production and application
of radiopharmaceuticals, for clinical and research
purpose. To create the educational program and training
that include application of International Basic Safety
Standards for Protection against Ionizing Radiation and
for the Safety of Radiation Sources (BSS) together with
Good Radiopharmaceutical Practice is one of general
starting point to cover all the aspect of the application
of radiopharmaceuticals for diagnostic, both SPECT
and PET and therapeutical purpose for all practices and
interventions.
Methods: To establish the program of education and
training for Good Radiation Safety Practice related to the
usage of radiopharmaceuticals is important tool for all
individuals working with radiopharmaceuticals. They
have a responsibility to take all reasonable precautions
to protect patients; to protect members of the general
public; to protect their colleagues; and most importantly to
protect themselves from unnecessary exposure to ionizing
radiation.
Education and suitable training that include regular and
continuing education as an formal and not formal approach
in: Design and construction of facilitieas of production and
application of radiopharmaceuticals;
Local radiation safety rules and procedures for quality
control;Preparedness;Equipment;
Monitoring of the personnel and environment.
Results: All types of education and training in
national and international level must to ensure that all
radiopharmaceutical preparations and administration
procedures should be carried under well-defined and
controlled conditions. Good housekeeping is important and
all work areas should be kept clean and tidy, all radionuclide
containers must be safely stored and readily available,
adequate supplies of consumables must be available
within easy reach of staff performing radiopharmacy
work, unnecessary visits to the radiopharmacy should be
discouraged and contaminated sharp items such as needles
must be safely stored behind shielding.
Regular obligatory records should be kept of: Receipt and
disposal of radioactive materials;
All individual preparations for patient administration,
including the patient’s name, radiopharmaceutical used,
activity and date; Quality control testing of the radionuclide
calibrator and other instruments
Regular surveys (preferably weekly) of contamination
must be performed. A decontamination kit should be held
in or near the radiopharmacy.
A sensitive radiation monitor must be available at all times
in the radiopharmacy for contamination checking, not only
of surfaces, but also ofhands, clothing and disposables.
Conclusions: To have well trained competent staff who
have the necessary skills and knowledge to deal with
radioactive pharmaceutical products must be the goal of
each institution involved in production and application of
radiopharmaceuticals including its own quality assurance
programme to ensure that the products administered to
patients are of the desired quality.
This requires to develop an appropriate education
and training for the radiation safety related to the
radiopharmaceuticals as one of the vital component in the
assurance of quality of administrated radiopharmaceuticals
Copper-64 based radiopharmaceuticals for brain tumors and hypoxia imaging
The most common and aggressive primary malignancy of the central nervous system is Glioblastoma that, as a wide range of malignant solid tumor, is characterized by extensive hypoxic regions. A great number of PET radiopharmaceuticals have been developed for the identification of hypoxia in solid tumors, among these, we find copper-based tracers. The aim of the current review paper was to provide an overview of radiocopper compounds applied for preclinical and clinical research in brain tumors and hypoxia imaging or therapy
Review Article 188 W/ 188 Re Generator System and Its Therapeutic Applications
The 188 Re radioisotope represents a useful radioisotope for the preparation of radiopharmaceuticals for therapeutic applications, particularly because of its favorable nuclear properties. The nuclide decay pattern is through the emission of a principle beta particle having 2.12 MeV maximum energy, which is enough to penetrate and destroy abnormal tissues, and principle gamma rays ( = 155 keV), which can efficiently be used for imaging and calculations of radiation dose
Iaea contribution to the development of <sup>64</sup>cu radiopharmaceuticals for theranostic applications
Copper-64 is a very attractive radioisotope with unique nuclear properties that allow using it as both a diagnostic and therapeutic agent, thus providing an almost ideal example of a theranostic radionuclide. A characteristic of Cu-64 stems from the intrinsic biological nature of copper ions that play a fundamental role in a large number of cellular processes. Cu-64 is a radionuclide that reflects the natural biochemical pathways of Cu-64 ions, therefore, can be exploited for the detection and therapy of certain malignancies and metabolic diseases. Beside these applications of Cu-64 ions, this radionuclide can be also used for radiolabelling bifunctional chelators carrying a variety of pharmacophores for targeting different biological substrates. These include peptide-based substrates and immunoconjugates as well as small-molecule bioactive moieties. Fueled by the growing interest of Member States (MS) belonging to the International Atomic Energy Agency (IAEA) community, a dedicated Coordinated Research Project (CRP) was initiated in 2016, which recruited thirteen participating MS from four continents. Research activities and collaborations between the participating countries allowed for collection of an impressive series of results, particularly on the production, preclinical evaluation and, in a few cases, clinical evaluation of various 64Cu-radiopharmaceuticals that may have potential impact on future development of the field. Since this CRP was finalized at the beginning of 2020, this short review summarizes outcomes, outputs and results of this project with the purpose to propagate to other MS and to the whole scientific community, some of the most recent achievements on this novel class of theranostic 64Cu-radiopharmaceticals
IAEA Activities on 67Cu, 186Re, 47Sc Theranostic Radionuclides and Radiopharmaceuticals
International audienceDespite interesting properties, the use of 67Cu, 186Re and 47Sc theranostic radionuclides in preclinical studies and clinical trials is curtailed by their limited availability due to a lack of widely established production methods. An IAEA Coordinated Research Project (CRP) was initiated to identify important technical issues related to the production and quality control of these emerging radionuclides and related radiopharmaceuticals, based on the request from IAEA Member States. The international team worked on targetry, separation, quality control and radiopharmaceutical aspects of the radionuclides obtained from research reactors and cyclotrons leading to preparation of a standard recommendations for all Member States. The CRP was initiated in 2016 with fourteen participants from thirteen Member States from four continents. Extraordinary results on the production, quality control and preclinical evaluation of selected radionuclides were reported in this project that was finalized in 2020. The outcomes, outputs and results of this project achieved by participating Member States are described in this minireview
IAEA activities on 67Cu, 186Re, 47Sc Theranostic radionuclides and Radiopharmaceuticals
Despite interesting properties, the use of 67Cu, 186Re and 47Sc theranostic radionuclides in preclinical studies and clinical trials is curtailed by their limited availability due to a lack of widely established production methods. An IAEA Coordinated Research Project (CRP) was initiated to identify important technical issues related to the production and quality control of these emerging radionuclides and related radiopharmaceuticals, based on request from IAEA Member States. The international team worked on targetry, separation, quality control and radiopharmaceutical aspects of the radionuclides obtained from research reactors and cyclotrons leading to preparation of a standard recommendations for all Member States. The CRP was initiated in 2016 with fourteen participants from thirteen Member States from four continents. Extraordinary results on the production, quality control and preclinical evaluation of selected radionuclides were reported in this project that was finalized in 2020. The outcomes, outputs and results of this project achieved by participating Member States are described in this minireview